Cargando…
Atorvastatin (Lipitor) by MCR
[Image: see text] A concise and convergent synthesis of the atorvastatin, the best-selling cardiovascular drug of all time, is presented. Our approach is based on an Ugi reaction, which shortens the current synthetic route and is advantageous over the published syntheses.
Autores principales: | Zarganes-Tzitzikas, Tryfon, Neochoritis, Constantinos G., Dömling, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421582/ https://www.ncbi.nlm.nih.gov/pubmed/30891146 http://dx.doi.org/10.1021/acsmedchemlett.8b00579 |
Ejemplares similares
-
Multicomponent Reactions: “Kinderleicht”
por: Neochoritis, Constantinos G., et al.
Publicado: (2020) -
Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
por: Neochoritis, Constantinos G, et al.
Publicado: (2019) -
MCR Scaffolds Get Hotter with (18)F-Labeling
por: Zarganes-Tzitzikas, Tryfon, et al.
Publicado: (2019) -
Application of Silver Nanoparticles in the Multicomponent
Reaction Domain: A Combined Catalytic Reduction Methodology to Efficiently
Access Potential Hypertension or Inflammation Inhibitors
por: Iordanidou, Domna, et al.
Publicado: (2018) -
Late-Stage Copper-Catalyzed Radiofluorination of an Arylboronic Ester Derivative of Atorvastatin
por: S. Clemente, Gonçalo, et al.
Publicado: (2019)